| Revision as of 11:55, 3 March 2013 editAztecWarrior28 (talk | contribs)Extended confirmed users2,379 editsNo edit summary← Previous edit | Revision as of 02:59, 4 March 2013 edit undoAndrewman327 (talk | contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers, Rollbackers34,253 editsm →References: cleaning up new articles using AWB (8853)Next edit → | ||
| Line 40: | Line 40: | ||
| {{monoclonals for immune system}} | {{monoclonals for immune system}} | ||
| ⚫ | {{monoclonal-antibody-stub}} | ||
| ] | ] | ||
| ⚫ | {{monoclonal-antibody-stub}} | ||
Revision as of 02:59, 4 March 2013
Pharmaceutical compound| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | interferon gamma-induced protein |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| Chemical and physical data | |
| Formula | C6502H10024N1736O2026S48 |
| Molar mass | 146.5 kDa g·mol |
Eldelumab is a monoclonal antibody designed for the treatment of Crohn's disease and ulcerative colitis.
This drug was developed by Bristol-Myers Squibb.
References
- Statement On A Nonproprietary Name Adopted By The USAN Council - Eldelumab, American Medical Association.
 | This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it. |